Medanta Q2 FY27 Revenue Surges 33.6% YoY to ₹14,690 Million, EBITDA Up 60.2%
Global Health Limited reported a 33.6% YoY revenue increase to ₹14,690 million for Q2 FY27. Operating EBITDA grew 60.2% to ₹3,701 million, with margins at 25.2%. PAT rose 38.3% to ₹2,191 million. The company added 74 beds and plans ₹62,390 million capex over 4-5 years.
The significant year-on-year financial growth, coupled with strategic expansion plans and a substantial capex outlay, indicates a high impact on the company's future performance and market position.
The company reported strong year-on-year growth in revenue, operating EBITDA, and profit after tax, driven by increased patient volumes and improved margins. Expansion plans and a robust capex pipeline also contribute positively.
Global Health Limited (MEDANTA) announced its financial results for the Second Quarter and Half Year ended September 30, 2026. The company reported a significant 33.6% year-on-year (YoY) revenue growth for Q2 FY27, reaching ₹14,690 million (₹1469 crore). This growth was primarily driven by an increase in patient volumes, with inpatient count rising by 29.5% and outpatient count by 37.9% YoY.
Operating EBITDA saw a substantial increase of 60.2% YoY to ₹3,701 million (₹370.1 crore), with margins improving to 25.2% from 21.0% in the prior year's comparable quarter. Profit After Tax (PAT) for the quarter was ₹2,191 million (₹219.1 crore), a 38.3% increase from ₹1,584 million in Q2 FY26, with PAT margins at 14.9% compared to 14.4% YoY.
The company added 74 new beds across its network during the quarter, contributing to a total census bed capacity of 3,115 beds. Occupancy rates increased to approximately 67% on an expanded bed capacity. Average Revenue Per Patient (ARPP) stood at ₹2.06 lakh, a slight increase from ₹2.01 lakh in Q2 FY26, while the Average Length of Stay (ALOS) decreased to 2.89 days from 3.06 days.
Cluster 2 hospitals (Lucknow, Patna, and Noida) showed particularly strong performance, with revenue growing by 63.2% YoY and Operating EBITDA increasing by 110.0% YoY to ₹1,837 million, with margins improving to 31.7%. The Noida hospital achieved EBITDA breakeven during the quarter. International Patients Revenue grew by 30.3% YoY, and the OPD Pharmacy business saw a 52.9% YoY revenue increase.
Looking ahead, Medanta has outlined a significant capex plan of approximately ₹62,390 million over the next 4-5 years, including expansions in various cities like Mumbai, Guwahati, Varanasi, and Ghaziabad, alongside a planned medical school and guest house. The company maintained a strong balance sheet with a net cash surplus of ₹7,815 million as of September 30, 2026.
What to do with a filing like this
Global Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Global Health Limited. Read the original for the full detail.